Home » Stocks » BXRX

Baudax Bio, Inc. (BXRX)

Stock Price: $1.08 USD -0.14 (-11.16%)
Updated Oct 28, 2020 11:02 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 19.75M
Revenue (ttm) 349,000
Net Income (ttm) -88.38M
Shares Out 18.37M
EPS (ttm) -4.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.08
Previous Close $1.21
Change ($) -0.14
Change (%) -11.16%
Day's Open 1.15
Day's Range 1.07 - 1.15
Day's Volume 1,094,787
52-Week Range 1.07 - 10.14

More Stats

Market Cap 19.75M
Enterprise Value n/a
Earnings Date (est) Feb 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 18.37M
Float 18.03M
EPS (basic) n/a
EPS (diluted) -4.81
FCF / Share -1.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.92M
Short Ratio 7.10
Short % of Float 10.67%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 56.60
PB Ratio n/a
Revenue 349,000
Operating Income -38.11M
Net Income -88.38M
Free Cash Flow -28.27M
Net Cash 30.13M
Net Cash / Share 1.64
Gross Margin -86.20%
Operating Margin -10,920.06%
Profit Margin -25,324.60%
FCF Margin -8,101.43%
ROA -41.69%
ROE n/a
ROIC 4,009.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.67*
(799.53% upside)
Low
7.00
Current: $1.08
High
11.00
Target: 9.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-47.07-65.04-48.26
Net Income-32.56-73.67-61.08
Shares Outstanding9.359.35-
Earnings Per Share-3.48-7.88-
Operating Cash Flow-50.04-59.75-43.27
Capital Expenditures-1.48-3.45-1.29
Free Cash Flow-51.53-63.20-44.56
Cash & Equivalents17.74--
Total Debt0.77--
Net Cash / Debt16.97--
Assets54.2135.0232.76
Liabilities70.9310395.22
Book Value-16.72-68.35-62.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Baudax Bio, Inc.
Country United States
Employees 24
CEO Gerri A. Henwood

Stock Information

Ticker Symbol BXRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BXRX

Description

Baudax Bio, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.